Enzo Biochem, Inc.
Other OTCTotal Valuation
Enzo Biochem, Inc. carries a market capitalization of 36.59M, placing it among publicly traded companies globally. Its enterprise value stands at -8.58M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 36.59M |
| Enterprise Value | -8.58M |
Share Statistics
Enzo Biochem, Inc. currently has 52.40M shares outstanding.
| Shares Outstanding | 52.40M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.91, and the price-to-book ratio stands at -0.08.
| PE Ratio | N/A |
| PS Ratio | 0.91 |
| PB Ratio | -0.08 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | -1.64 |
| P/OCF Ratio | -1.64 |
Enterprise Valuation
| EV / Sales | 0.34 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
Enzo Biochem, Inc. maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.84 |
| Quick Ratio | 2.41 |
| Debt / Equity | 6.92 |
| Debt / EBITDA | -0.30 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -26.86 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.41 |
Stock Price Statistics
Enzo Biochem, Inc.'s stock has declined approximately -37.03874% over the past 52 weeks. The 50-day moving average sits at 0.66, while the 200-day moving average is 0.63.
| Beta (5Y) | N/A |
| 52-Week Price Change | -37.03874% |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 0.63 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Enzo Biochem, Inc. generated 27.48M in revenue and converted that into -21.08M in net income, yielding earnings per share of -0.15. EBITDA reached -9.92M, while operating income came in at -11.28M.
| Revenue | 27.48M |
| Gross Profit | 11.77M |
| Operating Income | -11.28M |
| Pretax Income | -7.84M |
| Net Income | -21.08M |
| EBITDA | -9.92M |
| EBIT | -11.28M |
| Earnings Per Share (EPS) | -0.15 |
Balance Sheet
Enzo Biochem, Inc. holds 36.69M in cash and equivalents against 3.00M in total debt, resulting in a net debt position of -36.49M. Total book value stands at -301.61M, with working capital of 31.27M providing operational flexibility.
| Cash & Cash Equivalents | 36.69M |
| Total Debt | 3.00M |
| Net Debt | -36.49M |
| Equity (Book Value) | -301.61M |
| Book Value Per Share | -5.77 |
| Working Capital | 31.27M |
Cash Flow
Enzo Biochem, Inc. produced -15.32M in operating cash flow over the past twelve months.
| Operating Cash Flow | -15.32M |
| Capital Expenditures | N/A |
| Free Cash Flow | -15.32M |
| FCF Per Share | -0.29 |
Margins
Enzo Biochem, Inc. operates with a gross margin of 42.84, reflecting its pricing power and cost economics. The operating margin of -41.05 and net profit margin of -76.73 provide insight into operational efficiency.
| Gross Margin | 42.84 |
| Operating Margin | -41.05 |
| Pretax Margin | -28.54 |
| Profit Margin | -76.73 |
| EBITDA Margin | -36.12 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 36.54 |
| FCF Yield | -61.01 |
Stock Splits
Enzo Biochem, Inc.'s most recent stock split took place on October 21, 2004 with a 20:21 split ratio.
| Last Split Date | 10/21/2004 |
| Split Ratio | 20:21 |
Scores
Enzo Biochem, Inc. posts an Altman Z-Score of -5.47, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -5.47 |